Reaction Details | |||
---|---|---|---|
Report a problem with these data | |||
Target | Mu-type opioid receptor | ||
Ligand | BDBM50122549 | ||
Substrate/Competitor | n/a | ||
Meas. Tech. | ChEMBL_145593 (CHEMBL749738) | ||
IC50 | 7±n/a nM | ||
Citation | Hanessian, S; Parthasarathy, S; Mauduit, M; Payza, K The power of visual imagery in drug design. Isopavines as a new class of morphinomimetics and their human opioid receptor binding activity. J Med Chem46:34-48 (2002) [PubMed] Article | ||
More Info.: | Get all data from this article, Assay Method | ||
Mu-type opioid receptor | |||
Name: | Mu-type opioid receptor | ||
Synonyms: | M-OR-1 | MOP | MOR-1 | MOR1 | MUOR1 | Mu Opioid Receptor | Mu opiate receptor | OPIATE Mu | OPRM1 | OPRM_HUMAN | hMOP | mu-type opioid receptor isoform MOR-1 | ||
Type: | G Protein-Coupled Receptor (GPCR) | ||
Mol. Mass.: | 44789.51 | ||
Organism: | Homo sapiens (Human) | ||
Description: | P35372 | ||
Residue: | 400 | ||
Sequence: |
| ||
BDBM50122549 | |||
n/a | |||
Name | BDBM50122549 | ||
Synonyms: | 4N,13N-dibenzyl-17-cyclopropylmethyl-16-methyl-17-azatetracyclo[7.6.2.02,7.010,15]heptadeca-2(7),3,5,12,14-pentaene-4,13-diamine | ||
Type | Small organic molecule | ||
Emp. Form. | C35H39N3 | ||
Mol. Mass. | 501.7043 | ||
SMILES | C[C@@H]1[C@@H]2C3=CC(CC[C@H]3[C@H](Cc3ccc(NCc4ccccc4)cc23)N1CC1CC1)=NCc1ccccc1 |w:30.36,wU:2.2,9.28,8.7,1.0,t:3,TLB:0:1:3.8:24.11.10,23:24:25.1:3.8,THB:12:11:25.1:3.8,26:25:3.8:24.11.10,7:8:25.1:24.11.10,(11.14,-1.71,;10.05,-2.81,;6.2,-1.55,;6.2,,;6.2,1.56,;7.54,2.33,;8.88,1.56,;8.88,,;7.54,-.77,;7.76,-4.64,;6.2,-4.64,;4.87,-3.87,;3.54,-4.64,;2.21,-3.87,;2.21,-2.32,;.85,-1.53,;-.49,-2.29,;-.49,-3.83,;-1.84,-4.59,;-1.84,-6.13,;-.51,-6.9,;.83,-6.13,;.83,-4.59,;3.54,-1.55,;4.87,-2.32,;9.2,-4.09,;10.15,-5.29,;9.59,-6.73,;8.4,-7.69,;9.84,-8.25,;7.54,3.87,;6.2,4.64,;4.87,3.87,;3.55,4.64,;2.23,3.9,;2.23,2.35,;3.56,1.59,;4.87,2.36,)| | ||
Structure |